Targeted protein degradation (TPD) using the endogenous Ubiquitin Proteasome System (UPS) represents a fundamentally new approach to drug discovery. This potentially allows proteins that cannot be modulated by conventional small molecule inhibitors to be brought under therapeutic control. Plexium has developed an ultra-high-throughput platform for screening solid phase synthesized DNA encoded libraries (DELs) in phenotypic cell-based assays in custom nanoliter-scale microfluidic devices. This platform enables the efficient identification of novel monovalent or molecular glue degraders utilizing highly diverse chemical libraries and various high content assays in intact cells…